Inhibition of Human Osteoclast Differentiation by Kynurenine through the Aryl-Hydrocarbon Receptor Pathway
Open Access
Abstract
Aryl-hydrocarbon receptor (AhR) is a ligand-activated transcription factor and regulates differentiation and function of various immune cells such as dendritic cells, Th17, and regulatory T cells. In recent studies, it was reported that AhR is involved in bone remodeling through regulating both osteoblasts and osteoclasts. However, the roles and mechanisms of AhR activation in human osteoclasts remain unknown. Here we show that AhR is involved in human osteoclast differentiation. We found that AhR expressed highly in the early stage of osteoclastogenesis and decreased in mature osteoclasts. Kynurenine (Kyn), formylindolo[3,4-b] carbazole (FICZ), and benzopyrene (BaP), which are AhR agonists, inhibited osteoclast formation and Kyn suppressed osteoclast differentiation at an early stage. Furthermore, blockade of AhR signaling through CH223191, an AhR antagonist, and knockdown of AhR expression reversed Kyn-induced inhibition of osteoclast differentiation. Overall, our study is the first report that AhR negatively regulates human osteoclast differentiation and suggests that AhR could be good therapeutic molecule to prevent bone destruction in chronic inflammatory diseases such as rheumatoid arthritis (RA).Keywords
Funding Information
- National Research Foundation of Korea (2019R1A2C1083857, 2019R1A2C2004214, 2021R1A6A1A03038899)
This publication has 33 references indexed in Scilit:
- Aryl Hydrocarbon Receptors in Osteoclast Lineage Cells Are a Negative Regulator of Bone MassPLOS ONE, 2015
- Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymesProceedings of the National Academy of Sciences, 2013
- Interleukin‐27 inhibits human osteoclastogenesis by abrogating RANKL‐mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signalingArthritis & Rheumatism, 2010
- A role for the aryl hydrocarbon receptor and the dioxin TCDD in rheumatoid arthritisRheumatology, 2008
- The molecular understanding of osteoclast differentiationBone, 2007
- Novel Compound 2-Methyl-2H-pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) Prevents 2,3,7,8-TCDD-Induced Toxicity by Antagonizing the Aryl Hydrocarbon ReceptorMolecular Pharmacology, 2006
- The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cellsOncogene, 2005
- Mechanistic insight into osteoclast differentiation in osteoimmunologyJournal of Molecular Medicine, 2005
- Osteoclast differentiation and activationNature, 2003
- c-myc Is Required for Osteoclast DifferentiationJournal of Bone and Mineral Research, 2002